Trial Profile
A Randomized, Double-blind, Placebo-controlled Study in Hemodialysis Patients with Secondary Hyperparathyroidism
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Jan 2022
Price :
$35
*
At a glance
- Drugs Cinacalcet (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 14 Jun 2016 New trial record